Introduction
Cancer gene therapy, the genetic modification of cells for therapeutic benefit against cancer, holds great promise. Encouraging antitumoral efficacy and safety have been demonstrated in preclinical animal models using varied approaches, including tumor suppressor gene replacement, prodrug-activating enzyme expression and immunomodulatory strategies. However, clinical trial results have been disappointing to date. Although encouraging safety has been demonstrated, in general, antitumoral efficacy has been minimal or non-existent. 1, 2 The reasons for this are certainly varied, but clearly two major limitations have been the inability to achieve (1) sufficiently high levels of gene expression in (2) sufficiently large numbers of target cells to result in clinical benefit. These limitations need to be overcome if cancer gene therapy is ever to fulfil its promise.
One novel and potentially fruitful approach to achieving higher level gene expression and more widespread infection within tumors is the use of replication-selective agents. 3, 4 Alternatively referred to as 'oncolytic' agents or as 'cancer biotherapy', this approach capitalizes on the fact that microbial agents such as viruses and bacteria can replicate within human tissues to levels that are many logs higher than the input 'dose', kill the infected cell and subsequently spread to adjacent cells. 5, 6 Replicationselective viruses have been studied for their utility Correspondence: D Kirn cation was generally transient (Ͻ10 days), however, and was variable depending on tumor histology. Single agent efficacy has been limited to date (0-14% local tumor regression rates). In combination with chemotherapy, however, encouraging antitumoral activity has been demonstrated. These clinical research results demonstrate the potential of this novel treatment platform, as well as the hurdles to be overcome. Novel replication-selective agents with improved potency are needed. Gene Therapy (2001) 8, 89-98.
against cancer for nearly a century. 7 However, up until the last decade investigators had used only wild-type or tumor-tropic isolates from a variety of viral species. [8] [9] [10] Following the development of recombinant DNA technology and molecular biology advances, viruses could be engineered to enhance the desired anti-cancer phenotype.
Martuza et al 11 first demonstrated the potential utility of genetically engineered replication-selective viruses for cancer treatment almost 10 years ago. Since that time tumor selectivity has been genetically engineered or enhanced in a number of replication-selective microbes, including herpesvirus, 12 ,13 adenovirus 14, 15 and Salmonella typhimurium. 3, 5 In addition, inherently replication-selective agents have been developed for cancer treatment 3 including Newcastle disease virus, 16 autonomous parvoviruses, 17 reovirus, 18 vaccinia, 19 poliovirus 20 and VSV. 21 Although preclinical data reported with these agents have been encouraging, many critical questions have awaited results from clinical trials. Microbial agents such as adenovirus have complex biologies, potentially including species-specific interactions with host cell machinery and/or immune response effectors. 22, 23 Antitumoral efficacy and safety studies have been performed in rodent or primate models, and all published animal tumor model data with replication-selective adenoviruses have come from immunodeficient mouse-human tumor xenograft models. 6, 24, 25 Therefore, data from cancer patients have been eagerly awaited. After over 4 years of clinical development with dl1520, roughly 15 clinical trials have been completed and analyzed involving approximately 250 patients. This review is the first attempt to assess the data from these studies in aggregate to determine what we have learned about: (1) the clinical utility of dl1520 (Onyx-015), specifically; and (2) about the biology and potential utility of replication-selective adenoviruses, in general. Future research directions are also discussed.
Background: dl1520 (Onyx-015)
One approach to engineering replication selectivity is to delete viral genes that are necessary for efficient replication in normal cells but are expendable in tumor cells. The deletion approach was first described with herpesvirus. Martuza et al 26 showed the therapeutic potential of the thymidine kinase gene-deleted herpesvirus dlsptk initially. Subsequently, this group constructed G207; this virus has the lacZ gene inserted into the ribonucleotide reductase gene 27 and has mutations in both copies of the ICP34.5 gene. dl1520 (Onyx-015) was the first adenovirus described to mirror this approach. McCormick hypothesized that an adenovirus with deletion of a gene encoding a p53-inhibitory protein, E1B-55kD, would be selective for tumors that had already lost p53 function.
14 P53 function is lost in the majority of human cancers through mechanisms including gene mutation, overexpression of p53-binding inhibitors (eg mdm2, human papillomavirus E6) or loss of proteins that indirectly modulate p53 function such as p14 ARF . [28] [29] [30] E1B-55kD gene deletion from adenovirus was associated with decreased replication and cytopathogenicity in p53(+) tumor cells versus matched p53(−) tumor cells, relative to wild-type adenovirus, in RKO and H1299 cells. 14, 31 In addition, normal epithelial and endothelial cells were shown to be relatively resistant to dl1520-induced cytopathic effects and replication. 15 Based on these data, clinical trials were initiated. Subsequently, our group and others demonstrated that the mechanism of selectivity of this virus was far more complex in vitro than was originally proposed (see section labeled 'Controversy . . .' in this manuscript). Nevertheless, the definitive data on the clinical utility of this virus have to come from clinical trials.
A staged approach to the clinical development of replication-selective agents dl1520 (Onyx-015, now CI-1042, Pfizer Corporation, Groton, CT, USA) is a novel agent with a novel mechanism of action. This virus was the first genetically engineered, replication-selective virus to be used in humans. We predicted that both toxicity and efficacy might be dependent on multiple factors including: (1) the inherent ability of a given tumor to replicate and shed the virus; (2) the location of the tumor to be treated (eg intracranial versus peripheral); and (3) the route of administration of the virus. In addition, we felt it would be critical to obtain biological data on viral replication, antiviral immune responses and their relationship to antitumoral efficacy in the earliest phases of clinical development.
We therefore designed and implemented a novel staged clinical research and development approach ( Figure 1 ). The goal of this approach was to increase systemic exposure to the virus sequentially only after safety with more localized delivery had been demonstrated. Following demonstration of safety and biological activity by the intratumoral route, trials were sequentially initiated to study intracavitary instillation (initially intraperitoneal), intra-arterial infusion (initially hepatic artery) and eventually intravenous administration. In addition, only patients with advanced and incurable cancers were initially enrolled on trials. Only after safety had been demonstrated in terminal cancer patients were trials initiated for patients with premalignant conditions. Finally, clinical trials of combinations with chemotherapy were initiated only after the safety of dl1520 as a single agent had been documented by the relevant route of administration.
Intratumoral indications
Cancer patients can benefit from the effective local therapy of an established tumor mass if the target tumor mass causes morbidity or death before other masses do. For example, patients with recurrent glioblastoma multiforme or head and neck cancer frequently die from local tumor progression without evidence of distant metastases. In contrast, eradication of a localized skin lesion in a patient with widespread pulmonary or CNS metastases is unlikely to be of benefit. Patients with recurrent head and neck carcinomas were enrolled into the initial clinical trials because most suffer severe morbidity, and even mortality, from the local/regional progression of treatment-refractory tumors; therefore, intratumoral administration had the potential to cause substantial palliation and even survival prolongation. This population was also chosen because of the accessibility of superficial tumors for direct injection and biopsy in the outpatient clinic setting. Finally, patients with tumors in superficial neck and oral locations would presumably better tolerate peritumoral inflammation and swelling than patients with intraparenchymal tumors (eg intracranial, intrapulmonary or intrahepatic). Once the safety of intratumoral injection was demonstrated in the superficial neck and oral regions, trials of intratumoral injection in solid organs (pancreas, liver) were carried out.
Intracavitary indications
Tumor types that spread and/or cause complications primarily within specific body cavities are potentially amenable to intracavitary administration of therapeutic agents. Examples include mesothelioma (pleural cavity), ovarian carcinoma (peritoneal cavity) and recurrent superficial bladder carcinoma (bladder). In addition, several premalignant conditions are also amenable to superficial intracavitary administration, including Barrett's esophagus and oral dysplasias (eg oral leukoplakia). Intraperitoneal administration to patients with advanced, refractory ovarian carcinoma was followed by intra-esophageal instillation in patients with Barrett's esophagus. The virus was sequestered within the affected region of the esophagus following instillation through a WilsonCook catheter by occlusive proximal and distal balloons. Finally, oral dysplasias were targeted through administration as a mouthwash.
Vascular delivery: intra-arterial and intravenous administration
Although patients with the indications listed above can potentially benenfit from local-regional therapy, systemic antitumoral efficacy can have a much greater impact on overall cancer-related mortality. Preclinical studies proved that intravenous adenovirus could infect, replicate within and inhibit the growth of established metastatic tumors. 6 However, nude mouse-human tumor xenograft models were of unkown relevance to human cancer patients from both safety and efficacy standpoints. Targeted intra-arterial infusions were studied in the first intravascular trial. 32 Colorectal carcinoma metastases to the liver cause morbidity and death in a large proportion of these patients, and these metastases receive у90% of their blood flow from the hepatic artery. Hepatic artery infusions had therefore been used previously to target colorectal liver metastases with a variety of agents. 33 Once safety by this route of administration had been demonstrated, intravenous trials were initiated in patients with lung metastases.
Results from clinical trials with dl1520 (Onyx-015) Toxicity The toxicity findings from trials of dl1520 (Onyx-015) are outlined in Tables 1-3 . Data from phase I trials of intratu- Single dose/q4 wk none Fever (78) Asthenia (57) Nausea (43) Gene Therapy moral injections with dl1520 (Onyx-015) are outlined in Table 1 . Dosing on clinical trials was done on the basis of infectious units (plaque-forming units, p.f.u.), but it is now standard to dose on the basis of viral particles. Therefore, all doses used in this review are p.f.u. converted to particles (particle: p.f.u. ratio 20:1). No maximally tolerated dose or dose-limiting toxicities were identified following intratumoral injection doses of up to 2 × 10 12 particles. 34 This safety is true not only for tumors injected in superficial neck and oral sites, but also for intrahepatic and intra-pancreatic tumor masses, as well. 35 No clinically significant hepatitis or pancreatitis was demonstrated; transient low-grade episodes were rarely documented. Flu-like symptoms were the most common associated toxicities. No clear association between flu-like symptoms and viral dose or treatment cycle was demonstrable. Phase I/II and phase II trials reported a similar lack of clinically significant toxicities. 36, 37, 63 This safety is remarkable given the daily or even twice-daily dosing that was repeated every 1-3 weeks in the head and neck region or pancreas. Local complications of intratumoral injections in the pancreas appeared to be related to the endoscopic ultrasoundguided injection procedure rather than to the agent itself; these included bacteremia, cyst formation and a tear of the doudenal wall. 36 Each of these complications were avoided once procedural changes were made and prophylactic antibiotic treatment was mandated.
Intraperitoneal administration was also well-tolerated, in general (Table 3) . 38 Intraperitoneal administration was feasible at doses up to 10 13 particles divided over 5 days. The most common toxicities included fever, abdominal pain, nausea/vomiting and bowel motility changes (diarrhea, constipation). The severity of the symptoms appeared to correlate with tumor burden. Patients with heavy tumor burdens reached a maximally tolerated dose at 10 12 particles (dose-limiting toxicities were abdominal pain and diarrhea), whereas patients with a low tumor burden tolerated 10 13 without significant toxicity. No dose-limiting toxicities were reported at doses up to 2 × 10 12 particles (hepatic artery) 32 or 2 × 10 13 particles (intravenous). 39 Fever, chills and asthenia following intravascular injection were more common and more severe than after intratumoral injections (grade 2-3 fever and chills versus grade 1). Dose-related transaminitis was reported infrequently. The transaminitis was typically transient (Ͻ10 days) and low-grade (grade 1-2) and was not clinically relevant at doses up to 2 × 10 12 particles. However, at the highest intravenous doses administered (6 × 10 12 particles to 2 × 10 13 particles), AST/ALT levels reached approximately three to five times the upper limit of normal for the assay; although the maximally tolerated intravenous dose has not yet been defined, it may therefore be close to this dose. Further dose escalation was limited by virus supplies.
Viral replication
Viral replication was assessed by two methods during clinical trials with dl1520. The first was in situ hybridization for adenoviral DNA in tumor biopsy samples; replication was demonstrated by nuclear predominance of adenoviral DNA staining and associated cytopathic effects. The second method was to test blood samples for adenoviral genomes by quantitative PCR; since the initial input of viral genomes is cleared from the blood in 6-24 h, genomes in the blood on day 3 or after are indicative of viral replication. These two methods gave nearly identical results in patients with head and neck cancers.
Histologic analysis of tumor biopsies is attractive because the nature and distribution of the infected cells can be evaluated. However, the evaluation of biopsy samples to assess replication has severe limitations. First, false negatives are possible given the small amount of tissue obtained. Post-treatment biopsies can also be inevaluable if necrotic tissue is obtained. Ethical and practical considerations also limit the number of samples that can be obtained over time, particularly in tissues that are not superficial and therefore require invasive procedures to access them. Quantitative PCR is far more practical. Blood samples can be conveniently obtained and analyzed at multiple time-points. False negative results are possible, however, since the lower limit of detection is 10 4 genomes per milliliter and viral shedding into the bloodstream is required for detection. It was encouraging that the frequency of replication detected on several head and neck cancer trials by biopsy staining was nearly identical to that determined by plasma sample PCR testing. At this time, it appears that these two approaches each have merits and that they are complementary.
Viral replication has been documented at early timepoints after intratumoral injection in head and neck cancer patients by both tests. 37, 63 Approximately 70% of patients with either biopsy analysis or plasma testing by PCR had evidence of replication on days 1-3 after the last treatment. In contrast, days 14-17 samples were uniformly negative. This time-course for replication mirrors closely the clinical evidence for biological activity (eg local inflammation and necrosis). Intratumoral injection of liver metastases (primarily colorectal) led to similar PCR results at the highest doses of a phase I trial (unpublished data); high quality biopsy samples could not be collected given the location of these tumors. Patients with injected pancreatic tumors, in contrast, showed no evidence of viral replication by plasma PCR or fine needle aspiration (Gene Therapy, in press). Similarly, intraperitoneal dl1520 could not be shown reproducibly to infect ovarian carcinoma cells within the peritoneum. 38 None of the plasma PCR samples was positive and only one of 12 peritoneal fluid samples was faintly positive in 3-5 cells. Therefore, different tumor types can vary dramatically in their permissiveness for viral infection and replication.
Proof of concept for tumor infection following intraarterial or intravenous administration with human adenovirus has been achieved. Approximately half of the roughly 25 patients receiving hepatic artery infusions of 2 × 10 12 particles were positive by PCR 3-5 days following treatment. 32 Three of four patients with metastatic carcinoma to the lung treated intravenously with у2 × 10 12 particles were positive for replication by PCR on day 3 (±1). 39 Therefore, it is feasible to infect distant tumor nodules following intravenous or intra-arterial administration.
Perhaps the optimal method to determine the exact extent and duration of intratumoral replication is to resect the entire tumor mass at predetermined timepoints after injection. This strategy was used in patients with surgically resectable head and neck tumors (S Morley and S Kaye, Beatson Institute, Glasgow). Half of the tumor mass was injected; the contralateral tumor half was used as an internal control during evaluation of replication, necrosis and immune cell infiltration. Viral replication results were very similar to those obtained through biopsies and/or blood PCR; replication was common within р72 h after injection (particularly in p53 mutant tumors), but it was short-lived. Reproducible treatment-associated immune cell infiltrations were not seen in these tumors. No replication or necrosis induction was demonstrable following direct injection of normal buccal mucosa. Transient tumor-selective replication was therefore confirmed on this study (S Morley, personal communication).
Gene Therapy
Immune response Neutralizing antibody titers to the coat (Ad5) of dl1520 were positive but relatively low in roughly 50-60% of all clinical trial patients at baseline. 34, 40 Antibody titers increased uniformly following administration of dl1520 by any of the routes tested, in some cases to levels Ͼ1:80 000. 34 Antibody increases occurred regardless of evidence for replication or shedding into the bloodstream. Flu-like symptoms (fevers, rigors) were significantly more frequent and severe with intravascular administration than with intratumoral injections. 41 The acute inflammatory cytokine response to hepatic arterial infusion was evaluated using RT-PCR for specific cytokine mRNAs from buffy coat leukocyte samples. 32 The levels of the following were determined before treatment, 3 h post-and 18 h post-treatment: IL-1, IL-6, IL-10, interferon-gamma, tumor necrosis factor. Significant increases were demonstrated within 3 h for IL-1, IL-6, tumor necrosis factor and to a lesser extent interferon-gamma; all cytokines were back down to pretreatment levels by 18 h. In contrast, IL-10 did not increase until 18 h. Future analyses will attempt to correlate clinical outcomes with cytokine levels.
Patients with elevated neutralizing antibody titers before treatment were less likely to have evidence of viral DNA in the blood 3-5 days after treatment; 32 intraarterial administration was more sensitive to antibody inhibition (P = 0.01) than intratumoral administration (P = 0.09) 32 (and unpublished data). This effect cannot simply be ascribed to enhanced clearance of the virus from the plasma by antibodies; viral pharmacokinetics were unchanged between cycle 1 (low antibody titers) and cycle 3 (high antibody titers). 32 Whether plasma PCR negativity reflects decreased viral replication, decreased shedding or both is not clear at this time.
Efficacy with dl1520 (Onyx-015) as a single agent The single agent efficacy of ONYX-015 is outlined in Table 4 . Two phase II trials enrolled a total of 40 patients with recurrent head and neck cancer. 42, 63 Tumors were treated aggressively with six to eight daily needle passes for 5 consecutive days (30-40 needle passes per 5 day cycle; n = 30) and 10-15 per day on a second trial (50-75 needle passes per cycle; n = 10). The median tumor volume on these studies was approximately 25 cm 3 ; an average cm 3 of tumor therefore received an estimated four to five needle passes per cycle. Despite the intensity of this treatment, the unconfirmed response rate (у50% shrinkage at a single point in time) was only 13%. Therefore, even in a tumor that can be extensively and repeatedly injected, the majority of injected tumors did not objectively respond. Interestingly, there was no correlation between evidence of antitumoral activity and neutralizing antibody levels at baseline or after treatment. 37, 63 No objective responses were demonstrated in patients with tumor types that could not be directly and aggressively injected (due to their deep locations). Although some evidence of minor shrinkage or necrosis was obtained, no objective responses were documented with intratumoral injection of either pancreatic cancer (phase I and II trials; n = 43 patients) 36 or gastrointestinal carcinomas (phase I trial, primarily colorectal; n = 19 patients) (unpublished data). Similarly, no responses were seen following intraperitoneal administration (phase I; n = 16 ovarian cancer patients) 38 or following intravenous
Gene Therapy Single dose/q 1 wk 0/9 (0) (3 wk on, 1 off) a Non-necrotic cross-sectional area used for regression assessment (ie necrotic area subtracted from total cross-sectional area). All regressions refer to shrinkage of the injected tumor mass only (ie distant, non-injected tumors not included). All regressions were in tumors with a p53 gene mutation. b Evaluable patients defined as those receiving Ͼ1 cycle of therapy and measurable tumor at baseline and at least one occasion Ͼ6 weeks after treatment initiation (ie patients without follow-up tumor measurements after 1+ cycles of treatment were excluded). Intent-to-treat analysis includes all patients receiving at least one dose of ONYX-015. The confirmed responses reflect those that were confirmed to be durable for у4 weeks on an intent-to-treat basis. c Responses of single agent ONYX-015 determined after 4 cycles (on day 35) on the pancreatic EUS phase I/II trial. Subsequent cycles given with chemotherapy. administration in nine patients with metastatic carcinomas (phase I; n = 9). 39 No objective responses were demonstrated during the virus only treatment stage of a phase I/ II hepatic artery infusion trial (n = 33 patients, predominantly colorectal cancer metastases); responses were only seen on this trial in combination with chemotherapy (see below). 32 Of note, many of the patients described above were treated on the phase I portions of these trials in which tumor response was not a primary endpoint. In addition, many of these patients had tumors that were refractory to standard therapies and/or were highly fibrotic, potentially making responses less likely. In summary, single agent responses across all studies were rare, and therefore combinations with chemotherapy were explored.
Efficacy in combination with chemotherapy: virotherapychemotherapy augmentation Cancer treatment failure results when tumors become resistant to standard therapies. Therefore, novel treatments that are not cross-resistant with standard chemotherapies (ie work by different mechanisms) are needed. Combination therapy with agents that act by different mechanisms should make the emergence of resistant disease less likely. Ideally, the toxicities associated with these agents would be non-overlapping, thus allowing safe combination treatment. Adenoviruses are therefore well-suited for use in combination with chemotherapies. 4, 43 Preclinical mouse tumor model studies have demonstrated that these agents can be safely and effectively combined, and that efficient viral replication can still occur despite concomitant chemotherapy with cisplatin and 5-fluorouracil. 64 Evidence for a favorable interaction between adenoviral therapy and chemotherapy has been obtained on multiple trials (Table 5) . Encouraging clinical data have been obtained in patients with recurrent head and neck cancer treated with intratumoral dl1520 in combination with intravenous cisplatin and 5-fluorouracil. 44 Thirty-seven patients were treated and 19 responded (54%, intent-totreat; 63%, evaluable); this compares favorably with response rates to chemotherapy alone in previous trials (30-40%, generally). The time-to-tumor progression was also superior to previously reported studies. However, comparisons with historical controls are unreliable. We therefore used patients as their own controls whenever possible (n = 11 patients). Patients with more than one tumor mass had a single tumor injected with dl1520 while the other mass(es) was left uninjected. Since both masses were exposed to chemotherapy, the effect of the addition of viral therapy to chemotherapy could be assessed. The dl1520-injected tumors were significantly more likely to respond (P = 0.017) and less likely to progress (P = 0.06) than were non-injected tumors. Non-injected control tumors that progressed on chemotherapy alone were subsequently treated with Onyx-015 in some cases; two of the four injected tumors underwent complete regressions. These data illustrate the potential of viral and chemotherapy combinations. The clinical utility of dl1520 in this indication will be definitively determined in a randomized phase III trial.
A phase I/II trial of dl1520 administered by hepatic artery infusion in combination with intravenous 5-fluorouracil and leukovorin was carried out (n = 33 total). 32 Following phase I dose escalation, 15 patients with colorectal carcinoma who had previously failed the same chemotherapy were treated with combination therapy after failing to respond to dl1520 alone; one patient underwent a partial response and 10 had stable disease (2-7+ months). Chemosensitization of colorectal liver metastases is therefore possible via hepatic artery infusions, although the magnitude and frequency of this effect remains to be determined. In contrast, data from a phase I/II trial studying the combination of dl1520 and gemcitabine chemotherapy (n = 21 patients) were not encouraging; the combination resulted in only two responses, and these patients had not received prior gemcitabine. Therefore, potential synergy was demonstrated with dl1520 and chemotherapy in two tumor types that supported viral replication (head and neck, colorectal), but not in a tumor type that was resistant to viral replication (pancreatic).
Results from clinical trials with dl1520 (Onyx-015): summary dl1520 has been extremely well-tolerated at the highest practical doses that could be administered (2 × 10 12 -2 × 10 13 ) by intratumoral, intraperitoneal, intra-arterial and intravenous routes. The lack of clinically significant toxicity in the liver or other organs was remarkable. Flulike symptoms (fever, rigors, asthenia) were the most common toxicities and were increased in patients receivGene Therapy ing intravascular treatment. Acute inflammatory cytokines (especially IL-1 and IL-6) increased within 3 h following intra-arterial infusion. Neutralizing antibodies increased in all patients, regardless of dose, route or tumor type. Viral replication was documented in head and neck and colorectal tumors following intratumoral or intra-arterial administration. Neutralizing antibodies did not block antitumoral activity in head and neck cancer trials of intratumoral injection. However, viral replication/shedding into the blood was inhibited by neutralizing antibodies; intra-arterial virus was more sensitive to antibody inhibition than was intratumorally injected virus. Single agent antitumoral activity was limited in head and neck cancers that could be repeatedly injected directly (13% unconfirmed regression rate). No objective responses were documented with single agent therapy in phase I or I/II trials in patients with pancreatic, colorectal or ovarian carcinomas. A favorable and potentially synergistic interaction with chemotherapy was discovered in multiple tumor types and by multiple routes of administration.

Controversy regarding the mechanism of action of dl1520
The original experiments demonstrated that E1B-55kD gene deletion from adenovirus was associated with decreased replication and cytopathogenicity in p53(+) tumor cells versus matched p53(−) tumor cells, relative to wild-type adenovirus, in RKO cells.
14 In addition, normal epithelial and endothelial cells were shown to be relatively resistant to dl1520-induced cytopathic effects and replication. 15 Based on these data clinical trials were initiated. Subsequently, however, our group and others demonstrated that the mechanism of selectivity of this virus was far more complex in vitro than was originally proposed. First, p53 function can be lost in many cancers through mechanisms besides gene mutation; therefore, a lack of correlation with the p53 gene status of tumors was not unexpected in retrospect. 43, 45, 46 The precise role of p53 in the inhibition of adenoviral replication has not been clearly defined to date. In addition, other adenoviral proteins also have p53 inhibitory effects (eg E4ORF6). 47 Finally, E1B-55kD itself has important viral functions that are unrelated to p53 inhibition (eg viral mRNA transport, host cell protein synthesis shut-off). 48, 52 Therefore, the replication selectivity of this E1B-55kD deletion mutant may be complicated by numerous factors.
15,31,45,49 dl1520 (Onyx-015) has been extensively studied in vitro by many groups, and conflicting data on the role of p53 in modulating dl1520 replication and/or c.p.e. have come from different cell systems; no p53 effect was demonstrated in matched U2OS cells, for example. 46 In the HCT116 cell system, viral replication was inhibited by expression of p14 ARF in a p53 gene wild-type tumor line but not in the matched p53(−) tumor line, suggesting that loss of p14 ARF expression may prevent p53-mediated blockage of viral replication; this effect was relatively minor, however (one-half log). 65 Clinical trials were ultimately necessary to determine the clinical utility of dl1520.
Future directions: Why has dl1520 (Onyx-015) failed as a single agent for refractory solid tumors to date?
Future improvements with this approach will be possible if the reasons for dl1520 failure as a single agent, and relative success in combination with chemotherapy, are uncovered. Factors that are specific to this adenoviral mutant as well as factors that may be generalizable to other viruses and/or bacteria should be considered. Regarding this particular adenoviral mutant, it is important to remember that this virus is attenuated relative to wild-type adenovirus in most tumor cell lines in vitro and in vivo, including even p53 mutant tumors. 31, 45, 46, 50 This is not an unexpected phenotype since this virus has lost critical E1B-55kD functions that are unrelated to p53, including viral mRNA transport. 51, 52 Innate and acquired immune responses to the virus may be critical. Of note, a second deletion in the E3B gene region of dl1520 may make this virus more sensitive to innate antiviral immune effectors (eg TNF-alpha); 51, 53 an immunocompetent animal model will need to be identified in order to explore the role of the immune response. Factors likely to be an issue with any virus include barriers to intratumoral spread, antiviral immune responses, inadequate viral receptor expression (eg CAR, integrins) and other mechanisms that are as yet unidentified.
Future directions: improving the efficacy of replication-selective agents
Given the high degree of safety but inadequate single agent efficacy of dl1520 against advanced solid tumors, second generation viruses will clearly be engineered for greater potency. For example, a promising adenoviral E1A mutant has been described that demonstrates not only tumor selectivity but also significantly greater antitumoral efficacy in vivo compared with dl1520 (all models tested) and even wild-type adenovirus (in a breast cancer metastasis model). 50, 54 Similar results have been reported with another E1A mutant. 55 Potency can also be improved by arming viruses with therapeutic genes (eg prodrug-activating enzymes), [56] [57] [58] or even utilizing prodrug-activating enzyme genes already present in the virus; 59 however, prodrug conversion can inhibit viral replication in some models. 57, 59 Viral coat modifications may be beneficial if inadequate CAR expression plays a role in the resistance of particular tumor types. 60 Improved systemic delivery may require novel formulations or coat modifications, as well as suppression of the humoral immune response. Finally, we must identify the mechanisms leading to the potential synergy between replicating adenoviral therapy and chemotherapy. This understanding may then allow us to bolster this interaction. In addition to adenovirus, other viral species are being developed. 18, 26, 61 Since intratumoral spread also appears to be a substantial hurdle for viral agents, inherently motile agents such as bacteria may hold great promise for this field. 62 The clinical development of the first-generation adenovirus dl1520 (Onyx-015) has taught us a great deal about the hurdles to be overcome with the replication-selective adenovirus approach. However, this novel therapeutic platform clearly has great potential to improve and prolong the lives of cancer patients.
